Last updated: October 7, 2026
Detrol LA, the extended-release formulation of tolterodine, was a major antimuscarinic treatment for overactive bladder before generic erosion and newer therapies reduced its commercial relevance. Pfizer inherited the product through its acquisition of Pharmacia, and Detrol revenue reached approximately $1 billion annually at its peak. The product then entered a mature, price-competitive phase as generic tolterodine formulations became available and branded competition intensified.
Detrol LA’s commercial decline reflects four factors: loss of core patent protection, substitution by generic tolterodine, competition from Detrol’s immediate-release version and other antimuscarinics, and migration toward branded extended-release products such as Myrbetriq.
What is Detrol LA and how does tolterodine work?
Detrol LA is a once-daily extended-release capsule containing tolterodine tartrate. It is approved for the treatment of overactive bladder with symptoms including urinary urgency, frequency and urge urinary incontinence.
Tolterodine is a competitive muscarinic receptor antagonist. The drug reduces involuntary detrusor muscle contractions in the bladder. Detrol LA uses an extended-release delivery system to maintain drug exposure over approximately 24 hours.
| Product |
Active ingredient |
Dosage form |
Typical administration |
Sponsor history |
| Detrol |
Tolterodine tartrate |
Immediate-release tablet |
Twice daily |
Pharmacia, later Pfizer |
| Detrol LA |
Tolterodine tartrate |
Extended-release capsule |
Once daily |
Pharmacia, later Pfizer |
| Generic tolterodine ER |
Tolterodine tartrate |
Extended-release capsule |
Once daily |
Multiple ANDA sponsors |
The FDA approved Detrol in 1998 and Detrol LA in 2000. Pharmacia developed and commercialized the product before Pfizer completed its acquisition of Pharmacia in 2003. Pfizer later marketed Detrol LA as part of its primary-care and specialty pharmaceutical portfolio (FDA, 2000; Pfizer, 2003).
When did Detrol LA lose exclusivity?
Detrol LA lost meaningful market exclusivity in the United States during the early 2010s. The basic tolterodine compound patent expired earlier, while later formulation protection extended the branded product’s defensive position.
| Protection or milestone |
Patent or date |
Commercial relevance |
| Tolterodine compound patent |
U.S. Patent No. 5,382,600 |
Core compound protection; expired around 2012 |
| Detrol LA formulation protection |
U.S. Patent No. 6,770,295 |
Extended-release formulation protection; expiration generally associated with the late 2010s or early 2020s, subject to patent-term adjustments |
| Detrol FDA approval |
1998 |
Established the immediate-release product |
| Detrol LA FDA approval |
2000 |
Created the once-daily extended-release franchise |
| Generic tolterodine ER entry |
Early 2010s |
Began sustained price and share erosion |
The commercial effect of patent expiry occurred before all potential listed patent terms had fully run because ANDA applicants could challenge listed patents through Paragraph IV certifications. Generic sponsors often enter after settlement agreements, court decisions, or negotiated launch dates.
Patent-term calculations can vary because of patent-term adjustment, pediatric exclusivity and terminal disclaimers. The Orange Book remains the controlling reference for patents listed against the approved NDA and any associated exclusivity information (FDA, n.d.-a).
What patents protect Detrol LA?
The Detrol LA estate centered on the active ingredient and the extended-release delivery system rather than a complex device or biologic manufacturing platform.
Composition and formulation patents
The key categories were:
- Tolterodine composition-of-matter protection.
- Pharmaceutical formulations containing tolterodine.
- Extended-release capsule technology.
- Dosage regimens based on once-daily administration.
- Manufacturing and controlled-release processes.
The formulation estate provided the most important commercial protection after compound patent expiry. Its value was limited by the relative simplicity of the active ingredient and the ability of generic manufacturers to develop bioequivalent extended-release products through the ANDA pathway.
Unlike biologic products, Detrol LA did not require biosimilar development. Generic manufacturers could rely on the reference product’s safety and efficacy findings by demonstrating pharmaceutical equivalence and bioequivalence.
Method-of-use patents
Method-of-use protection was less commercially important than formulation protection. Detrol LA’s primary approved use, treatment of overactive bladder, was well established and not difficult to design around if generic companies could satisfy FDA bioequivalence requirements.
No durable method-of-use barrier comparable to a narrowly defined oncology indication or orphan-disease patent estate controlled the market.
What was the financial trajectory of Detrol LA?
Detrol became one of the largest products in the overactive-bladder market during the early and mid-2000s. Pfizer’s public reporting indicates that Detrol revenue was approximately $1 billion per year around its peak, although annual filings did not always separate Detrol LA from the broader Detrol franchise or report every dosage form independently.
| Period |
Financial position |
Main driver |
| 1998-2000 |
Launch and adoption phase |
FDA approval and conversion from immediate-release use |
| 2001-2005 |
Peak commercial period |
Once-daily convenience and strong primary-care prescribing |
| 2006-2009 |
Mature branded phase |
Continued large installed base but increasing competition |
| 2010-2013 |
Decline begins |
Generic challenges, patent pressure and therapeutic substitution |
| 2014 onward |
Mature or residual brand phase |
Generic pricing, reduced promotion and portfolio deprioritization |
Pfizer’s annual reports identified Detrol among its important pharmaceutical brands during the peak period. Reported sales were broadly in the $1 billion range in the middle of the decade, followed by a sustained decline as competition increased and the franchise approached loss of exclusivity (Pfizer, 2005, 2006, 2007).
The product’s margin profile changed substantially after generic entry. Before erosion, Detrol LA benefited from branded pricing and a relatively low-cost small-molecule manufacturing process. After generic launch, net revenue fell faster than underlying prescription demand because payers substituted lower-cost alternatives and pharmacy benefit managers reduced reimbursement for the branded product.
Which companies challenged Detrol LA patents?
Generic pharmaceutical companies challenged Detrol LA through the ANDA process. The principal commercial participants in the tolterodine market included manufacturers such as Mylan, Teva, Sandoz, Watson, Actavis and other suppliers that developed generic tolterodine products.
Paragraph IV challenges generally created four possible outcomes:
- The reference sponsor sued the ANDA applicant.
- The patent was upheld and generic launch was delayed.
- The patent was invalidated or found not infringed.
- The parties settled, allowing an agreed launch date.
A Paragraph IV filing could trigger a 30-month stay of FDA approval under the Hatch-Waxman Act, subject to statutory limitations and litigation developments. The commercial outcome depended on the scope and remaining life of the listed formulation patents, not simply on the existence of a patent challenge (FDA, n.d.-b).
The Detrol LA litigation profile was less durable than litigation surrounding complex drug-device combinations or products with multiple later-generation patents. Once a generic manufacturer obtained approval and entered the market, other ANDA sponsors could follow rapidly.
What is the FDA regulatory and Orange Book status of Detrol LA?
Detrol LA was approved through the FDA’s traditional new drug application pathway. Generic tolterodine ER products were approved through abbreviated new drug applications.
The relevant regulatory structure is:
| Regulatory issue |
Detrol LA position |
| Reference product |
FDA-approved NDA product |
| Generic pathway |
ANDA with bioequivalence demonstration |
| Biosimilar pathway |
Not applicable |
| Orange Book role |
Lists approved product, patents and exclusivity information |
| Clinical substitution |
Governed by state pharmacy laws, payer policy and product-level substitution rules |
| Current commercial status |
Generic-dominated mature market |
FDA approval of generic tolterodine ER did not require sponsors to repeat the full clinical development program used for Detrol LA. This materially reduced development cost and shortened the path to commercialization.
How does Detrol LA compare with competing overactive-bladder drugs?
Detrol LA competed in a crowded market against older antimuscarinics and newer mechanisms.
| Product |
Mechanism |
Differentiating factor |
Commercial effect on Detrol LA |
| Oxybutynin |
Antimuscarinic |
Low-cost tablets, patches and gel |
Increased price pressure |
| Solifenacin, Vesicare |
Antimuscarinic |
Once-daily branded alternative |
Took branded share |
| Fesoterodine, Toviaz |
Antimuscarinic |
Pfizer-linked later-generation product |
Expanded internal substitution options |
| Darifenacin, Enablex |
Antimuscarinic |
Receptor selectivity positioning |
Added branded competition |
| Mirabegron, Myrbetriq |
Beta-3 adrenergic agonist |
Non-antimuscarinic mechanism |
Increased therapeutic switching |
| Trospium |
Antimuscarinic |
Generic and branded versions |
Expanded low-price competition |
Myrbetriq changed the competitive discussion because it offered a different mechanism and avoided some anticholinergic tolerability concerns. Antimuscarinic products remained clinically relevant, but physicians and patients had more options when dry mouth, constipation, cognitive concerns or other adverse effects affected treatment persistence.
Detrol LA retained practical advantages as a once-daily oral formulation, but those advantages became insufficient to sustain branded pricing after generic entry.
What generic entry risks exist for Detrol LA?
Detrol LA’s generic-entry risk was high because the product had:
- A chemically defined small-molecule active ingredient.
- No biologic comparability barrier.
- An established FDA-approved reference product.
- A relatively straightforward oral dosage form.
- Multiple potential ANDA manufacturers.
- Limited protection from narrow method-of-use claims.
- A large historical prescription base that supported generic competition.
The main technical barrier was development of an extended-release formulation that matched the reference product’s release profile and met FDA bioequivalence requirements. That barrier was meaningful but manageable for experienced generic manufacturers.
Once several generic suppliers entered, the market likely moved through the standard sequence of price reduction, formulary preference, branded prescription decline and reduced promotional spending.
How strong is the Detrol LA patent estate?
The Detrol LA patent estate was commercially moderate before generic entry and weak after the principal formulation protections expired or became subject to successful challenges.
Its strengths were:
- Early compound protection.
- A distinct once-daily extended-release product.
- A large and commercially attractive market.
- The ability to delay some generic approvals through patent litigation or settlement.
Its weaknesses were:
- Small-molecule chemistry that was suitable for ANDA development.
- Limited manufacturing complexity.
- No biosimilar or device-specific regulatory barrier.
- Few durable indications outside the core overactive-bladder market.
- Availability of multiple competing antimuscarinic products.
The estate was therefore effective at building a long commercial life but less capable of supporting premium pricing after loss of exclusivity.
What licensing deals affected Detrol LA?
The central transaction affecting Detrol was Pfizer’s acquisition of Pharmacia in 2003. The deal transferred Pharmacia’s commercial rights and product portfolio, including Detrol, to Pfizer (Pfizer, 2003).
Detrol LA was primarily an internally controlled Pfizer-Pharmacia product rather than a franchise shaped by a major later-stage licensing transaction. Its commercial trajectory depended more on acquisition ownership, lifecycle management and generic competition than on royalty-bearing external partnerships.
What patent litigation and settlement issues affected Detrol LA?
The key litigation issue was whether ANDA applicants could launch before the expiration of listed formulation patents. Patent disputes involving Detrol LA would have focused on:
- Validity of extended-release formulation claims.
- Infringement by generic release profiles.
- Patent-term calculations.
- Paragraph IV certifications.
- Settlement dates and possible authorized-generic strategies.
After generic entry, litigation value declined because the branded product no longer controlled the full market. The economic focus shifted from blocking entry to preserving residual branded demand, managing payer contracts and reducing manufacturing and promotional costs.
What is the current market outlook and revenue exposure for Detrol LA?
Detrol LA is a mature, genericized product. Its current revenue exposure for Pfizer is materially lower than during the peak period, and Pfizer’s public financial reporting no longer treats Detrol as a major growth driver.
The remaining commercial opportunity is concentrated in:
- Patients who remain on the branded product.
- Markets with slower generic substitution.
- Countries where branded reimbursement persists.
- Retail channels with limited formulary enforcement.
- Patients or physicians with established familiarity with tolterodine ER.
The principal risks are continued price compression, declining prescriptions, therapeutic substitution and product discontinuation or reduced commercial support. The product has little strategic value as a growth asset but can retain residual cash flow where manufacturing costs are low and regulatory maintenance expenses are limited.
How does Detrol LA compare with Pfizer’s newer urology products?
Pfizer’s later urology strategy included Toviaz, the extended-release formulation of fesoterodine. Toviaz provided a newer branded antimuscarinic option but remained exposed to the same broad category pressures: generic substitution, anticholinergic tolerability concerns and competition from beta-3 agonists.
| Factor |
Detrol LA |
Toviaz |
| Active ingredient |
Tolterodine |
Fesoterodine |
| Mechanism |
Antimuscarinic |
Antimuscarinic |
| Dosing |
Once daily |
Once daily |
| Lifecycle position |
Older, genericized |
Later-generation product, also exposed to generic erosion |
| Commercial protection |
Compound and formulation patents |
Later patent estate and newer launch position |
| Current strategic role |
Mature residual brand |
Lifecycle successor with limited long-term insulation |
Key Takeaways
- Detrol LA is Pfizer’s extended-release tolterodine product for overactive bladder.
- The product reached approximately $1 billion in annual sales during its peak commercial period.
- Pharmacia developed Detrol, and Pfizer acquired the franchise through its 2003 Pharmacia transaction.
- U.S. exclusivity eroded during the early 2010s as generic tolterodine products entered the market.
- The key intellectual-property defenses were the tolterodine compound patent and extended-release formulation patents.
- Detrol LA had high generic-entry risk because it is a small-molecule oral product approved through an ANDA-compatible pathway.
- Biosimilar risk is not relevant; generic substitution is the applicable competitive threat.
- Myrbetriq and other newer therapies increased therapeutic competition beyond the antimuscarinic class.
- Detrol LA is now a mature, generic-dominated product with limited strategic growth potential.
FAQs About Detrol LA Patent Expiration, Generics, and Market Value
Is Detrol LA still available in the United States?
Branded Detrol LA has a limited commercial presence compared with its peak period, while generic tolterodine extended-release products provide the principal supply in the U.S. market.
What is the generic name for Detrol LA?
The generic name is tolterodine tartrate extended-release capsules, commonly described as tolterodine ER.
Did Detrol LA have pediatric exclusivity?
Detrol LA’s principal commercial protection came from patent and regulatory exclusivity associated with the product and its formulation. Any pediatric exclusivity must be assessed from the FDA Orange Book entry and applicable historical regulatory records.
Is tolterodine ER therapeutically equivalent to Detrol LA?
FDA-approved generic tolterodine ER products may be therapeutically equivalent when assigned the applicable Orange Book equivalence rating. Substitution remains subject to the specific product rating, state law and payer policy.
Why did Detrol LA sales fall after 2010?
Sales declined because generic tolterodine entered the market, branded reimbursement weakened, Pfizer reduced reliance on the product, and physicians gained access to competing antimuscarinic and beta-3 agonist therapies.
References
-
Food and Drug Administration. (2000). Detrol LA: Prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (n.d.-b). Abbreviated new drug application approvals and patent certifications. U.S. Department of Health and Human Services.
-
Pfizer Inc. (2003). Annual report 2003. Pfizer Inc.
-
Pfizer Inc. (2005). Annual report 2005. Pfizer Inc.
-
Pfizer Inc. (2006). Annual report 2006. Pfizer Inc.
-
Pfizer Inc. (2007). Annual report 2007. Pfizer Inc.
-
U.S. Patent and Trademark Office. (1995). U.S. Patent No. 5,382,600: Tolterodine. U.S. Department of Commerce.
-
U.S. Patent and Trademark Office. (2004). U.S. Patent No. 6,770,295: Pharmaceutical compositions comprising tolterodine. U.S. Department of Commerce.
